Ibritumomab: profile and news

Biogen Idec Reports Full Year and Fourth Quarter 2005 Results Feb 15, 2006
...of Hematology (ASH) in Atlanta, demonstrate that patients may benefit from earlier and consolidated use of ZEVALIN(R) (Ibritumomab Tiuxetan) radioimmunotherapy ... - Genetic Engineering News,

... Go to the Article Feb 13, 2006
The drug Zevalin® (ibritumomab tiuxetan) is being studied in a clinical trial being conducted jointly at MD Anderson and Memorial Sloan-Kettering Cancer ... - CancerWise

Other information

Indication
For treatment of non-Hodgkin's lymphoma

Pharmacology
Zevalin binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin’s lympohomas. The antibody leads to selective killing of B-cells.

Mechanism Of Action
Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. The chelate tiuxetan, which tightly binds radioactive In-111 or Y-90, is covalently linked to the amino groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells.

Drug Category
Antineoplastic Agents

Brand Names/Synonyms
Ig gamma-2A chain C region, membrane-bound form; radiolabeled murine anti-CD20; Zevalin (IDEC Pharmaceuticals)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Murine anti-CD20 antibody

Chemical Formula
C6382H9830N1672O1979S54 >Mouse Anti-CD20 Light chain 1 >Mouse Anti-CD20 Heavy chain 1 >Mouse Anti-CD20 Light chain 1

Half Life
0.8 hours (mammalian reticulocytes, in vitro)

Drug Type
Approved Drug

# Accession No
BIOD00069

CAS Registry Number
174722-31-7